A double-blind, randomized, parallel, placebo-controlled study examining the effect of cross-linked polyelectrolyte in heart failure patients with chronic kidney disease

European Journal of Heart Failure

Volumn 14, Issue 8, 2012, Pages 922-930

  Costanzo, Maria Rosa ^a   Heywood, J Thomas ^b   Massie, Barry M ^c   Iwashita, Julie ^d   Henderson, Lee ^d   Mamatsashvili, Merab ^e   Sisakian, Hamayak ^f   Hayrapetyan, Hamlet ^g   Sager, Philip ^h   Van Veldhuisen, Dirk J ⁱ   Albrecht, Detlef ^d  

^a Edward Heart Hospital   (United States)

^b SCRIPPS CLINIC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Sorbent Therapeutics Inc   (United States)

^e Adapti Angio Cardiology Clinic   (Georgia)

^f YEREVAN STATE MEDICAL UNIVERSITY   (Armenia)

^g Erebouni Medical Center   (Armenia)

^h Sager Expert Consulting   (United States)

ⁱ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Chronic kidney disease; Cross linked polyelectrolyte; Heart failure; Potassium

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; CREATININE; CROSS LINKED POLYELECTROLYTE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; POLYELECTROLYTE; POTASSIUM; SODIUM; UNCLASSIFIED DRUG; UREA;

6 MIN WALK TEST; ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACIDOSIS; ACUTE HEART FAILURE; ADULT; AGED; APPETITE DISORDER; ARTICLE; ASCITES; BICARBONATE BLOOD LEVEL; BLOATING; BODY WEIGHT; CALCIUM BLOOD LEVEL; CARDIAC PATIENT; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT TOOL; COMORBIDITY; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FUNCTIONAL STATUS; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART RATE; HEMATOCRIT; HUMAN; HYDROTHORAX; HYPERTENSION; KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEW YORK HEART ASSOCIATION CLASSIFICATION; PARALLEL DESIGN; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TREATMENT WITHDRAWAL; UREA BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; VOMITING; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; CROSS-LINKING REAGENTS; DOUBLE-BLIND METHOD; ELECTROLYTES; EXERCISE TEST; FEMALE; HEART FAILURE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; POTASSIUM; QUALITY OF LIFE; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; SPIRONOLACTONE;

EID: 84864436219     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfs074     Document Type: Article

References (30)

1. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstram MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 Focused Update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 2009; 119:1977-2016.
2. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology 2001;96:132-143.
3. Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Studies of left ventricular dysfunction. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003;42:705-708.
4. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985; 103:1-6.
5. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal Syndrome. J Am Coll Cardiol 2008;52:1527-1539.
6. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JF, Wynne J. ADHERE scientific advisory committee and investigators. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007;13:422-430.
7. + transport. Am J Physiol 1988;255: F1269-F1275.
8. Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang I-Zu, on behalf of the PEARL-HF Investigators. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011;32: 820-828.
9. Bittner V, Weiner DH, Yusuf S, Rogers WJ, McIntyre KM, Bangdiwala SI, Kronenberg MW, Kostis JB, Kohn RM, Guillotte M, Greenberg B, Woods PA, Bourassa MG, for the SOLVD investigators. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. JAMA 1993; 270:1702-1707.
10. Teerlink Jr. Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure. Am Heart J 2003;145:S26-S33.
11. Spertus J, Peterson E, Conard MW, Heidenreich PA, Krumholz HM, McCullough PA, Pina I, Tooley J, Weintraub WS, Rumsfeld JS, Cardiovascular Outcomes Research Consortium. Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J 2005;150:707-715.
12. Pitt B, Zannad FWJ, Cody R, Castaigne A, Palensky J, Wittes J, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709-717.
13. Pitt B, RemmeW, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, for the eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
14. Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364: 11-21.
15. Sorensen MV, Matos JE, Praetorius HA, Leipziger J. Colonic potassium handling. Pflugers Arch 2010;459:645-656.
16. van der Meer P, van Veldhuisen DJ. To bind or not to bind: potassium-lowering drugs in heart failure. Eur Heart J 2011;32:791-792.
17. Bowling CB, Pitt B, Ahmed MI, Aban IB, Sanders PW, Mujib M, Campbell RC, Love TE, Aronow WS, Allman RM, Bakris GL, Ahmed A. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail 2010;3:253-260.
18. Huang IZ, Blok TM, Burdick M, Cope J, Halfon S, Mellinger KH, Park CK, Vanderlugt JT, Bushinsky DA, Albrecht D. RLY5016: a novel, non-absorbed, therapeutic polymer for serum potassium control. J Am Soc Nephrol 2010;21:p482A.
19. Teerlink J, Metra M, Felker M, Ponikowski P, Voors A, Davison Weatherly B, Marmor A, Katz A, Grzyboski J, Unemori E, Teichman SL, Cotter G. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009;373:1429-1439.
20. Massie BM, O'Connor CM, Metra M, Ponokowski P, Teerlink JR, Cotter G, Davison Weatherly B, Cleland JGF, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC, for the PROTECT Investigators and Committees. Rolofylline, an adenosine A1 receptor antagonist, in acute heart failure. N Engl J Med 2010;363:1419-1428.
21. Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, Dickstein K, Drazner MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van Veldhuisen DJ, Zannad F, Anker SD, Rhodes A, McMurray JJ, Filippatos G. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail 2010;12:423-433.
22. Schrier RW. Role of diminished renal function in cardiovascular mortality. Marker or pathogenetic factor? J Am Coll Cardiol 2006;47:1-8.
23. Costanzo MR, Saltzberg MT, Jessup M, Teerlink JR, Sobotka PA, for the UNLOAD investigators. Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD. J Cardiac Fail 2010;16:277-284.
24. Ali SS, Olinger CC, Sobotka PA, Dahle TG, Bunte MC, Blake D, Boyle AJ. Loop diuretics can cause clinical natriuretic failure: a prescription for volume expansion. Congest Heart Fail 2009;15:1-4.
25. Androne AS, Katz SD, Lund L, LaManca J, Hudaihed A, Hryniewicz K, Mancini DM. Hemodilution is common in patients with advanced heart failure. Circulation 2003; 107:226-229.
26. Shah MR, Hasselblad V, Gheorghiade M, Adams KF Jr, Swedberg K, Califf RM, O'Connor CM. Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. Am J Cardiol 2001;88:987-993.
27. Metra M, Ponikowski P, Dickstein K, McMurray JJ, Gavazzi A, Bergh CH, Fraiser AG, Jaarsma T, Pitsis A, Mohacsi P, Bohm M, Anker S, Dargie H, Brutsaert D, Komadja M. Advanced chronic heart failure: a position statement from the study group on advanced heart failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2007;9:684-694.
28. Peacock WF, Costanzo MR, De Marco T, Lopatin M, Wynne J, Mills RM, Emerman CL. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE Registry. Cardiology 2009;13:12-19.
29. Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, Yancy CW, Califf RM, Stevenson LW, Hill JA. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 2008;51:1268-1274.
30. Adams KF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149:209-216.